Cardamonin ameliorates insulin resistance induced by high insulin and high glucose through the mTOR and signal pathway

Planta Medica

Volumn 79, Issue 6, 2013, Pages 452-458

  Niu, Peiguang ^a   Zhang, Yuxuan ^a   Shi, Daohua ^a   Chen, Yaoyao ^a   Deng, Jie ^a  

^a Fujian Provincial Maternity and Child Health Hospital   (China)

Author keywords

cardamonin; glucose metabolism; insulin resistance; IRS 1; mTOR; S6K1; VSMCs

Indexed keywords

CARDAMONIN; DEOXYGLUCOSE; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; GLUCOSE METABOLISM; GLYCOGEN SYNTHESIS; HUMAN; HUMAN CELL; INSULIN RESISTANCE; NEGATIVE FEEDBACK; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD GLUCOSE; CELLS, CULTURED; CHALCONES; DEOXYGLUCOSE; GLYCOGEN; INSULIN; INSULIN RESISTANCE; MAMMALS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 84876694421     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0032-1328325     Document Type: Article

References (39)

1. Laplante M., Sabatini D. M. mTOR signaling in growth control and disease. Cell: 2012; 149 274 293
2. Zoncu R., Efeyan A., Sabatini D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol: 2011; 12 21 35
3. Yu X., Shen N., Zhang M. L., Pan F. Y., Wang C., Jia W. P., Liu C., Gao Q., Gao X., Xue B., Li C. J. Egr-1 decreases adipocyte insulin sensitivity by tilting PI3K/Akt and MAPK signal balance in mice. EMBO J: 2011; 30 3754 3765
4. Arellano-Plancarte A., Hernandez-Aranda J., Catt K. J., Olivares-Reyes J. A. Angiotensin-induced EGF receptor transactivation inhibits insulin signaling in C9 hepatic cells. Biochem Pharmacol: 2010; 79 733 745
5. Tanti J. F., Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol: 2009; 9 753 762
6. Vodenik B., Rovira J., Campistol J. M. Mammalian target of rapamycin and diabetes: what does the current evidence tell us? Transplant Proc: 2009; 41 S31 S38
7. Vinod P. K., Venkatesh K. V. Quantification of the effect of amino acids on an integrated mTOR and insulin signaling pathway. Mol Biosyst: 2009; 5 1163 1173
8. Vardatsikos G., Mehdi M. Z., Srivastava A. K. Bis(maltolato)-oxovanadium (IV)-induced phosphorylation of PKB, GSK-3 and FOXO1 contributes to its glucoregulatory responses (review). Int J Mol Med: 2009; 24 303 309
9. Zdychova J., Kazdova L., Pelikanova T., Lindsley J. N., Anderson S., Komers R. Renal activity of Akt kinase in obese Zucker rats. Exp Biol Med (Maywood): 2008; 233 1231 1241
10. Um S. H., DAlessio D., Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab: 2006; 3 393 402 (Pubitemid 43811780)
11. Chow Y. L., Lee K. H., Vidyadaran S., Lajis N. H., Akhtar M. N., Israf D. A., Syahida A. Cardamonin from Alpinia rafflesiana inhibits inflammatory responses in IFN-gamma/LPS-stimulated BV2 microglia via NF-kappaB signalling pathway. Int Immunopharmacol: 2012; 12 657 665
12. Fusi F., Cavalli M., Mulholland D., Crouch N., Coombes P., Dawson G., Bova S., Sgaragli G., Saponara S. Cardamonin is a bifunctional vasodilator that inhibits Ca(v)1.2 current and stimulates K(Ca)1.1 current in rat tail artery myocytes. J Pharmacol Exp Ther: 2010; 332 531 540
13. Yadav V. R., Prasad S., Aggarwal B. B. Cardamonin sensitizes tumour cells to TRAIL through ROS- and CHOP-mediated up-regulation of death receptors and down-regulation of survival proteins. Br J Pharmacol: 2011; 165 741 753
14. Zheng W., Shi D., Ji X., Han Y., Liao Q. Antiproliferation of cardamonin associated with mRNA expression of mTOR, Raptor and Rictor. China J Chin Mater Med: 2010; 35 2318 2323
15. Liao Q., Shi D. H., Zheng W., Xu X. J., Yu Y. H. Antiproliferation of cardamonin is involved in mTOR on aortic smooth muscle cells in high fructose-induced insulin resistance rats. Eur J Pharmacol: 2010; 641 179 186
16. Yamamoto N., Kawabata K., Sawada K., Ueda M., Fukuda I., Kawasaki K., Murakami A., Ashida H. Cardamonin stimulates glucose uptake through translocation of glucose transporter-4 in L6 myotubes. Phytother Res: 2011; 25 1218 1224
17. Adochio R., Leitner J. W., Hedlund R., Draznin B. Rescuing 3 T3-L1 adipocytes from insulin resistance induced by stimulation of Akt-mammalian target of rapamycin/p 70 S6 kinase (S6K1) pathway and serine phosphorylation of insulin receptor substrate-1: effect of reduced expression of p 85alpha subunit of phosphatidylinositol 3-kinase and S6K1 kinase. Endocrinology: 2009; 150 1165 1173
18. Lee J. Y., Cho H. K., Kwon Y. H. Palmitate induces insulin resistance without significant intracellular triglyceride accumulation in HepG2 cells. Metabolism: 2010; 59 927 934
19. Chen Y., Li Y., Wang Y., Wen Y., Sun C. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions. Metabolism: 2009; 58 1694 1702
20. Robinson K. A., Buse M. G. Mechanisms of high-glucose/insulin-mediated desensitization of acute insulin-stimulated glucose transport and Akt activation. Am J Physiol Endocrinol Metab: 2008; 294 E870 E881
21. Begum N., Ragolia L. High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p 38 MAPK activation. Am J Physiol Cell Physiol: 2000; 278 C81 C91 (Pubitemid 30101898)
22. Brown N. F., Stefanovic-Racic M., Sipula I. J., Perdomo G. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. Metabolism: 2007; 56 1500 1507 (Pubitemid 47562500)
23. Sipula I. J., Brown N. F., Perdomo G. Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation. Metabolism: 2006; 55 1637 1644 (Pubitemid 44827130)
24. Henriksen E. J. Dysregulation of glycogen synthase kinase-3 in skeletal muscle and the etiology of insulin resistance and type 2 diabetes. Curr Diabetes Rev: 2010; 6 285 293
25. Wang Z. B., Zeng H. C., Wei H. S., Yi G. H., Yu J., Wang Y. T., Zhang Y. L., Yin W. D. NO-1886 ameliorates glycogen metabolism in insulin-resistant HepG2 cells by GSK-3beta signalling. J Pharm Pharmacol: 2012; 64 293 301
26. Zhang H. H., Lipovsky A. I., Dibble C. C., Sahin M., Manning B. D. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell: 2006; 24 185 197 (Pubitemid 44574477)
27. Ishiki M., Klip A. Minireview: recent developments in the regulation of glucose transporter-4 traffic: new signals, locations, and partners. Endocrinology: 2005; 146 5071 5078 (Pubitemid 41653019)
28. Kampmann U., Christensen B., Nielsen T. S., Pedersen S. B., Orskov L., Lund S., Moller N., Jessen N. GLUT4 and UBC9 protein expression is reduced in muscle from type 2 diabetic patients with severe insulin resistance. PLoS One: 2011; 6 e27854
29. Veroux M., Corona D., Giuffrida G., Gagliano M., Sorbello M., Virgilio C., Tallarita T., Zerbo D., Giaquinta A., Fiamingo P., Macarone M., Li Volti G., Caglia P., Veroux P. New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression. Transplant Proc: 2008; 40 1885 1887
30. Kahan B. D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet: 2000; 356 194 202 (Pubitemid 30446974)
31. Tremblay F., Gagnon A., Veilleux A., Sorisky A., Marette A. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3 T3-L1 and human adipocytes. Endocrinology: 2005; 146 1328 1337 (Pubitemid 40289320)
32. Um S. H., Frigerio F., Watanabe M., Picard F., Joaquin M., Sticker M., Fumagalli S., Allegrini P. R., Kozma S. C., Auwerx J., Thomas G. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature: 2004; 431 200 205 (Pubitemid 39243474)
33. Krebs M., Brunmair B., Brehm A., Artwohl M., Szendroedi J., Nowotny P., Roth E., Furnsinn C., Promintzer M., Anderwald C., Bischof M., Roden M. The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes: 2007; 56 1600 1607 (Pubitemid 46842618)
34. Hwang S. L., Li X., Lee J. Y., Chang H. W. Improved insulin sensitivity by rapamycin is associated with reduction of mTOR and S6K1 activities in L6 myotubes. Biochem Biophys Res Commun: 2012; 418 402 407
35. Xie J., Herbert T. P. The role of mammalian target of rapamycin (mTOR) in the regulation of pancreatic beta-cell mass: implications in the development of type-2 diabetes. Cell Mol Life Sci: 2012; 69 1289 1304
36. Fraenkel M., Ketzinel-Gilad M., Ariav Y., Pappo O., Karaca M., Castel J., Berthault M. F., Magnan C., Cerasi E., Kaiser N., Leibowitz G. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes: 2008; 57 945 957
37. Miller A. M., Brestoff J. R., Phelps C. B., Berk E. Z., Reynolds T. H. 4th. Rapamycin does not improve insulin sensitivity despite elevated mammalian target of rapamycin complex 1 activity in muscles of ob/ob mice. Am J Physiol Regul Integr Comp Physiol: 2008; 295 R1431 R1438
38. McCubrey J. A., Steelman L. S., Chappell W. H., Abrams S. L., Franklin R. A., Montalto G., Cervello M., Libra M., Candido S., Malaponte G., Mazzarino M. C., Fagone P., Nicoletti F., Basecke J., Mijatovic S., Maksimovic-Ivanic D., Milella M., Tafuri A., Chiarini F., Evangelisti C., Cocco L., Martelli A. M. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget: 2012; 3 1068 1111
39. Mendoza M. C., Er E. E., Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci: 2011; 36 320 328